Roche Holding AG (OTCMKTS:RHHBY - Get Free Report)'s share price hit a new 52-week low on Thursday . The company traded as low as $29.80 and last traded at $30.02, with a volume of 3393938 shares trading hands. The stock had previously closed at $30.54.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on RHHBY shares. Morgan Stanley downgraded shares of Roche from an "equal weight" rating to an "underweight" rating in a report on Tuesday, January 16th. Argus reiterated a "hold" rating on shares of Roche in a research report on Monday, March 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, Roche presently has an average rating of "Hold" and an average price target of $40.00.
View Our Latest Stock Report on RHHBY
Roche Stock Down 1.7 %
The company has a debt-to-equity ratio of 0.75, a current ratio of 1.35 and a quick ratio of 1.04. The firm has a 50 day moving average price of $31.99 and a two-hundred day moving average price of $33.68.
Hedge Funds Weigh In On Roche
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its position in shares of Roche by 1,937.5% during the 4th quarter. Pacer Advisors Inc. now owns 1,099,659 shares of the company's stock valued at $39,841,000 after purchasing an additional 1,045,687 shares in the last quarter. Saratoga Research & Investment Management raised its holdings in shares of Roche by 19.4% during the third quarter. Saratoga Research & Investment Management now owns 2,268,479 shares of the company's stock valued at $76,969,000 after purchasing an additional 368,444 shares during the period. Tower Bridge Advisors acquired a new stake in shares of Roche in the 3rd quarter valued at about $2,811,000. Ramirez Asset Management Inc. bought a new stake in Roche in the 3rd quarter valued at about $2,575,000. Finally, Cable Hill Partners LLC acquired a new position in shares of Roche during the fourth quarter worth approximately $464,000.
Roche Company Profile
(
Get Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
